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O&rives. The purpose of this study was to investigate whether 
I) endothelin-I, a potent vasoconstrictor peptide, is involved in 
progression of pulmonary hypertension caused by congestive 
heart failure (CHF); and 2) whether long-term treatment with 
BQ-IU, an endothelin receptor antagonist, ameliorates pulmo- 
nary hypertension caused by CHF. 
Ruckgrvund. Congestive heart failore accompanies pulmnmuy 
hypertension, and the severity of pulmonsuy byperteasion is an 
important determinant of prognosis. Although we reported that 
production of endotbelin-1 is increcrsed in the failing heart in rats 
with CHF, it is not known wbether production of endotbelin-I in 
the lung is altered ‘q CHF. 
M&ods. Congestive heart failure was induced by comnafy 
artery ligation in rats. Expression of preprwndotbelin-1 messen- 
ger ribonucleic acid (mBNA) in the lung and kidney was deter- 
mined. Endothclin-1 staining (immunoreactiviv) in the lung was 
studied by immunohistocbemical analysis. EEects of long-term 
BQ-123 trostment on the rats were studied. 
The severity of congestive heart failure (CHF) often correlates 
with the degree of elevation of pulmonary artery pressure (1). 
Various heart and lung diseases are often accompanied by 
pulmonary hypertension, and the severity of this pulmonary 
hypertension is an important determinant of the prognosis of 
these patients (2). Although the exact factors that promote 
pulmonary hypertension in these diseases are unknown, it is 
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Rtwhs. Two weeks postoperatively, CHF accompanied by 
pulmonary hypertension developed in the rats (CHF rats). EX- 
pression of preproeadothelin-1 mRNA in the lung was markedly 
higher in tbe CHF rats than in the sham-operated rats, W~~KK 
that k the kidney did not diler between the two groups. 
Eadotbelia-I staining on the pulmonary vascular cndotb~lial Klls 
was IGBK intense in tbe CHF rats. BQ-123 treatment over a 
2-WKk period in the CHF rats greatly KdUKd right Venttihr 
systolic pressure and central venous pressure, but it did not rEect 
blood pressure or Iefl ventricular cnntractBity (peak positive Brst 
derivative of left ventricular pressure) in these mts. 
Conclrsions. Long-term I@-123 tmahnent greatly ameliorated 
pulmonary hypertension in the CHF rats. The present study 
suggests that enduthelis-1 plays an important role in the prqres- 
sion 01 pulmonary hypertension caased by CHF and that aa 
endotbelin receptor antagonist may be a new tbenpeutlc agent for 
CHF-induced pulmonary hypertension. 
(J Am Cdl Cadiol1996;28:1580-8) 
thought that there are some differences in mechanisms for 
progression of pulmonary hypertension among patients with 
heart and lung diseases (2). 
Endothelin-I. a potent vasoconstrictor peptide produced by 
vascular endothelial cells (3-6), possesses several properties 
that promote the development of pulmonary hypertension. 
First, rndothelin-I contracts isolated pulmonary vessels (6-g) 
and increases pulmonary vascular resistance (6,9). Second, it 
has a mitogenic effect on vascular smooth muscle cells (5,6,10) 
and fib&lasts (6;ll) that is consistent with a roll: in vascular 
remodeling, a prominent finding in pulmonary hypertensive 
stages. In rats with monocrotaline-induced pulmonary hyper- 
tension, a model of pulmonary hypertension caused by inflam- 
matory lung dise&, we (8) reported that long-term treatment 
with an endothelin receptor antagonist significantly inhibited 
the progression of pulmonary hypertension and p&en&d the 
thickening of the vascular walls of the pulmonary artery. These 
;l735-1097~15.oll 
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findings suggested that endogenous endothelin-l is involved in 
the progression of pulmonary hypertension caused by inflam- 
matory lung disease. However. it is not known whether 
endothelin-l is involved in the progression of pulmonary 
hypertension caused by CHF or whether long-term treatment 
with an endothelin receptor antagonist is effective in amclicF 
rating pulmonary hypertension caused by CHF. 
Plasma levels of endothelin-1 were reported to be increased 
in patients (12-14) and experimental animals (15.16) with 
CHF. In rats with CHF. we (16) reported that the heart is one 
of the origins of elevated plasma endothelin-l, because both 
messenger ribonucleic acid (mRNA) levels and mature peptide 
levels are markedly increased in the failing hearts of these rats. 
However, it is unclear whether the production of endothelin-l 
in the lungs is altered by CHF and it is not known whether 
long-term treatment with an endothelin receptor antagonist is 
effective in ameliorating pulmonary hypertension caused by 
CHF. Cody et al. (12) reported that plasma endothelin-1 
concentration correlates with the extent of pulmonary hyper- 
tension in patients with CHF, suggesting that elevated circu- 
lating endothelin-1 is related to the change in lung conditions 
in these patients. However, because the lung is an important 
organ for eliminating endothelin-1 from the circultiiion (17). it 
is not known whether this phenomenon is caused by increased 
production of endothelin-l in the lungs or decreased elimina- 
tion of endothelin-1 by the lung. Thus, the measurement of 
plasma endothelin-l ievzls has limitations for assessing pro- 
duction of endothelin-l in the lung. and there is no report that 
directly indicates whether or not endothelin-l production in 
the lung is increased in CHF. A study of the expression of 
prcproendothelin-1 mRNA in the lung would provide an 
answer to this question, as would a study of the distribuiion of 
endothelin-l staining in the lung section. 
The goal of this study was to investigate whether 
endothelin-1 is invohred in the progression of pulmonary 
hypertension caused by CHF in rats and whethei long-term 
treatment with an endothelin receptor antagonist amelioratg 
pulmonary hypertension ip these rats. For this purpose., we 
investigated the expression of preproendoihelin-1 mRNA in 
the lung of rats with CHF and the effti of long-term admin- 
istration of BQ-123. an endothelin-A reCeptOr (ETA receptor) 
antagonist (18). on pulmonary hypertension in rats with 
CHF induced by coronary artery ligation. Furthermore. we 
. 
Methds 
Experimental heart failure. The left corona? ant? was 
ligated in the rat to serve as 1 model of C’HF. Thi\ rtrt (CHF 
rat) i$ a well cstablishcci model (lU.31) in which prrthnph+ 
logic changes arc similar ta thow seen in ischcmic heart 
disease. that is. the most common contemporary cause of heart 
failure in humans (21). Left ven’ricular free wall myocardisl 
infarction was induced ia male Sprague-Dawle! :.n> (weighing 
170 to Y10 g) according to thr mcthtd of Pfcffcr ~1 al. (II)). as 
we (16) have previously described in detail. In brief. each rat 
was anesthetized with ether. A thoracotomg was performed. 
the heart was rapidly exteriorized and thr: proxima! portion of 
the left coronary artery was ligated with a 5-O <ilk suture. 
Except for coronary artev ligation. sham-operated rats under- 
went an identical proctdurc. About 604 of the rats ,*ith 
myocardial infarction died within the 1st 24 h. the surviving 
rats were maintained on standard rat chow and water ad 
libitum for 2 weeks. The study was approved by Universib of 
Tsukuba and conformed to the “Position of the American 
Heart Association on Research Animal Use” adopted by the 
Association in November 19&I. 
Seven days postoperatively. myocardial infarction was c-In- 
!irmed by electrocardiography: for these experiments ye used 
only rats habing abnormal Q waves in both limb leads 1 and 
aVL as these findings have been reported (20) to represent a 
medium to large infarct size. In a previous study we (16) found 
that under these conditions. and with electrocardiographic 
(ECG) assessment congestive heart failure develop in the rats 
within a few weeks after opcrati,.,. 
Hemodynamicmea -t rod tissue sampling. On the 
day of the experiment. the rats were anesthetized with sodium 
pentobarbital (50 m@g body weight intrapeitonealh). A 
microtip pressure transducer catheter (model WC-320. Millar 
Instruments) was inserted into the right carotid artery. After 
arterial blood pressure was measured. the catheter was ad- 
vanced into the left ventricle for evaluation of left ventricular 
pressure. These hemodynamic measurements were recorded 
by a polygraph system (AP6UlG amplifier and WT-687G 
thermal pen recorder. Nihon Ktir n. Tokyo. Japanj. More- 
over. the peak positive first derivative of left vemricular 
pressure (left ventricular +dP:‘dt,,,) was derived by active 
analog differentiation of the pressure signal differentiation 
amplifier (ED-6MG. Nihon Koden). Subsequently. a polycth- 
ylene catheter was inserted into the right jugular vein to 
measure central venous pressure and right ventricular pres- 
Sure. We (8.16) have previously descriid details of the 
methods for ‘&suring these hemod$namic variables. After 
hemodynamic measurement .‘1 blood timple aas collected 
from the right carotid artery. The lung and kidney were 
excised. weighed and frozen in hquid nitrogen. The heart was 
weighed after it was divided into the right and leti ventri- 
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cles (including the septum) under cold Krebs-Ringer solution. 
The plasma. and’ tissue samples were stored at -80°C for 
mature endothelin-1 peptide assay and for determination of 
preproendothclin-l mRNA expression. Some of these rats 
were used for immunohistochemical study. 
Sandwich-enzyme immunoassay to determine plasm . 
endothelin-1 levels. Plasma endorhelin-1 concentration was 
measured by a sandwich-enzyme immunoassay as we (8,16.22) 
hare previously described. In brief, each blood sample was 
placed in a chilled tube containing aprotinin (300 kallikrein- 
inhibiting U/ml) and EDTA (2 mg/ml) and was centrifuged at 
3,000 g for 15 min at 4°C. Sandwich-enzyme immunoassay for 
endothelin-1 was carried out as previously described by using 
immobilized mouse monoclonal antibody AwETN40. which 
recognizes the N-terminal portion of endothelin-1. and 
peroxidase-labeled rabbit antiendothelin-1. C-terminal peptide 
(15-21) Fab’ (8,16,22). The assay for endothelin-1 did not 
cross-react with endothelin3 or big-endothelin-1 (cross- 
reactivity <O.l%) (8,16,22). 
Northern blot analysis for preproendothelin-1 mRNA in 
the lung and kidney. Total RNA was prepared from the lung 
and kidney of sham-operated rats and the CHF rats, by 
selective precipitation in 3-molfliter lithium chloride and 
h-mol/liter urea as we (8,16,23) have previously described. In 
brief, total RNA (10 pg/Iane) from the lung and the kidney was 
separated by formamide/l .l% agarose gel electrophoresis and 
transferred onto nylon membranes (Hybond N. Amersham, 
Buckinghamshire, United Kingdom). The membranes were 
hybridized with a phosphorus-32-labeled complementary de- 
oxyribonucleic acid (cDNA) probe. After hybridization, the 
filter was finally washed in 0.1 X standard saline citrate/O.l% 
sodium dodecyl sulfate at 50°C and autoradiographed with 
intensifying screens at -80°C for 24 h. The prcproendothelin-1 
cDNA used as a probe in the present study was a previously 
described full-length insert of lambda r-endothelin-l-2 
(8,16,23) that was labeled by random priming with [alpha- 
phosphorus-321 deoxycitidine triphosphate (dCTP) (-3,000 
Cilmmol, Amersham). To normalize the preproendothelin-I 
signals for the loaded amounts and transfer efficiencies, the 
same membranes were rehybridized wtth beta-actin cDNA 
probe or ethidium bromide staining of 18s ribosomal RNA as 
the internal control. 
lmmunohistochemical analysis for endothelio-1 staining in 
the lungs. Tissue endothelin-1 staining (endothelin-l-like im- 
munoreactivity) was studied by using methods we (4,24) have 
previously described with minor modifications. In brief, after 
hemodynamic measurement, the lungs were subjected to per- 
fusion fixation with 0.01 mol/liter periodat+0.075 mol/Iiter 
lysin-2% parafcrmaldehyde solution, and fixed in this solution 
at 4°C overnight. The specimens were embedded in paraffin 
wax (melting point! SSOC). The sections were.eut into 3-km 
thickness and stained immunohistoehemically by using the 
biotin-streptoavidin-horseradish peroxidase method for, the 
detection of endothelin-1. Rabbit antiendothelin-1 polyclonal 
antibody (Peninsula Lab., Inc.) was used as the primary 
antibody. DeparatIinized sections were incubated with rabbit 
antiendothelin-I antibody (dilution 1:40(l) a! room tempera- 
ture. for 3 h. After being washed. the sections were incubated 
with secondary antibody diluted at l:lUO (biotinylated antirdb- 
bit immunogamma globulin; IBL, Fujioka, Japan) for 30 min, 
tlen with horseradish peroxidase-conjugated streptavidin di- 
lJ!ed at 1:lOO for 30 min. lmmunoreactive endothelin-1 prod- 
1;~s were visualized with 0.05% 3,3’-diamino-benzidine-O.O2’% 
‘,:!droperoxide. The slides were counterstained with methyl 
preen. The specificity of the immunoreuctivity was determined 
by an absorption test; that is, the consecutive sections were 
subjected to the same procedure with the use of the supema- 
tant of antiendothelin-1 antibody (dilution 1:loO) preabsorbed 
with synthetic endothelin-1 (20 PmoVliter) at 4°C for over- 
night. 
Erects of continuous BQ-123 infusion for 2 weeks on 
hemodynamic variables in the CHF rats. To investigate the 
effects of continuous BQ-123 infusion on the CHF rats, an 
osmotic minipump (model 2ML2, Alza Co.) was subcutane- 
ously implanted in the CHF rats and sham-operated rats on the 
day after myocardial infarction. BQ-123, donated by Dr. 
Masaru Nishikibe (Tsukuba Research Institute, Banyu Phar- 
maceutical Co., Tsukuba. Japan), was dissolved in saline 
solution. The osmotic minipumps contained either saline so- 
lution ah-e or saline solution and BQ-123. The rats were 
separated into three groups as follows: group 1. CHF rats 
receiving continuous BQ-123 infusion (15 mg/rat per day) for 
2 weeks, group 2, CHF rats receiving continuous saline infu- 
sion for 2 weeks; and group 3, sham-operated rats receiving 
continuous saline infusion for 2 weeks. 
Two weeks after the osmotic minipump was implanted, it 
was extracted under ether anesthesia 24 h before the experi- 
ments; that is, the hemodynamic measurements were per- 
formed after a 24-h washout period for BQ-123. The hemody- 
namic variables ‘vere measured under pentobarbital anesthesia 
(50 mg/kg body weight). 
Infarct size was measured as previously described (16.19) in 
both the CHF rats treated with saline solution and the CHF 
rats treated with BQ-123. In brief, after being weighed, the 
heart was immersion-lixed in 10% buffered formalin and then 
cut into four transverse sections from apex to base. These 
sections were processed in standard fashion and embedded in 
paraffin. A M.rsson trichrome-stained thin section from each 
level was projected, and the perimeters of the infarcted and 
noninfatcted epicardial and endocardial surfaces were traced 
and digitized. The infarcted portion (the proportion of the 
infarcted left ventricle) was calculated from these measure- 
ments (16.19). 
Statistical analysis. All statistical comparisons were per- 
formed by using a statistical package for the Macintosh 
personal computer (STAT VIEW, version 4.0, Abacus Con- 
cepts, Inc.). Differences between data for the CHF and sham- 
operated rats were assessed by ,an unpaired r test.. One-way 
analysis of variance followed by Bonferroni’s multiple compar- 
ison test was used for statistical comparison among the three 
treatment groups (see Table 2, Fig. 4). Differences were 
considered significant at p < 0.05. 
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Table 1: hrmodyamic Variables in Sham-Opcratcd Rats and CHF Rats 3 Wcckh Postopcintivcly 
HR mRP LVSP LV * dP&,,,, LVEDP RVSP RVEDP C\‘P 
Group (heats;min) (mm iig) (mm iig) (mm tlg’b) (mm Hgt (mm Hg (mm Hg) Iriim lig) 
Sham-opcrakd 37K z I4 II?-‘6 I%+5 X.hYh : 452 3.6 2 It.7 X.6 r 1.n 1.4 f 1t.z I .H _c (1.3 
rats (n = 6) 
CHF rals (n = h) 357 2 7 89 i 3 w-r-l 5.64X 2 335 19.3 . x kill x 2.3 10.f1 I 1.2 3.1 ” II:.8 
p value NS c: Ml < U.lJI .:: u.01 c: It.!11 < I~.ill -.’ n.u1 ,c u.u5 
- 
Values preented are mean value 2 SIN. CHF = congcltire hear1 failure; CVP = ccntrsl \LL~.IUS prcwrc: HR = hwn rw LVEDP -: IL? wmrirular 
end-diastolic pressure: LV+dP.‘dt,,,, = peak pnsilivc tint derivative of left vcntriculnl presrure: LVSP = Ich ventricular s!Mic prolsurc: mHP = mean hl& prcs+urc: 
RVEDP = riphI vemricular end-diaslolic pressure: RVSP = righr wnbicular syMic prcrsurc. 
Results 
Hemodynamic variables and tissue weights. Mean arterial 
blood pressure. left ventricular peak systolic pressure and left 
ventricular tdP/dt,,, were significant11 lower m the CHF rats 
than. in the sham-operated rats (Table 1). Left ventricular 
end-diastolic pressure was markedly elevated in the CHF rats 
(Table l), and right ventricular systolic, right ventricular 
end-diastolic and central venous pressures were significantly 
higher in the CHF rats than in the sham-operated rats (Table 
1). These data indicate that CHF accompanied by pulmonary 
hypertension developed in the CHF rats. 
The CHF rats weighed !CTS than the sham-operated rats 
(277 it 8 vs. 307 + 4 g. n = 6, p < 0.05), and their lung weight 
mass index for body weight was much higher (8.53 + 0.63 vs. 
3.90 2 0.14 mg/g, p < O.Ol), suggesting that they had pulmo- 
nary congestion. Right ventricular mass index for body weight 
was signilicantly higher in the CHF rats than in the sham- 
operated rats (1.17 2 0.09 vs. 0.60 2 0.02 mug, p < 0.01). but 
left ventrkzvlar mass index for body weight was not different in 
the two groups (2.31 2 0.08 vs. 2.17 -t 0.06 mglg, p = NS). 
Plasma eudothelio-1 level. The plasma endothelin-1 con- 
centralion of the CHF rats was -3.3-fold higher than that of 
the sham-operated rats (3.89 2 0.49 vs. 1.32 +- 0.10 pg/ml. n = 
6, p < 0.01). 
Expression of preproendothelin-1 mRNA in the lung and 
kidney, The expression of preproendothelin-1 mRNA in the 
lung of both the CHF rats and the sham-operated rats was 
determined by Northern blot analysis. Typical examples of the 
lung at 2 weeks after operation are shown in Figure 1. The 
expression of preproendothelin-1 mRNA in the lung in the 
CHF rats was much higher than that in the sham-operated rats 
(Fig. 1). Densitometric analysis of these blots corrected for the 
levels of beta-a&n mRNA, which was used as normalization 
for a constitutively expressed message in the lung. The densi- 
tometric ratio of (preproendothelin-1 mRNA)/(beta-actin 
mRNA) in the lung of the CHF rats was significantly higher 
than that, in the sham-operated rats (0.38 -C 0.04 vs. 0.15 f 
0.02, n =,5, p < 0.01). However. in the kidney, the expression 
of preproendothelin-1 mRNA did not differ between the two 
rat groups (Fig. 2). 
Inun~Wchemkal analysii lor endotMn-1 st&i&ia 
tfie 1~ The typical examples of endothelin-l staining (i.e.. 
endothelin-l-like immunoreactivity) in the rat lung demon- 
strated by immunohiiocbemical methods are shown in Figure 
3. The endothelin-1 staining (endothelin-1-like immunoreac- 
tivity) appeared brown (Fig. 3). The vascular endothelium was 
stained brown. indicating that endothelin-I is dis!ributed in the 
vascular endothelium of both the sham-operated rats (Fig. 3. 
left) and the CHF rats (Fig. 3. right). Figure 3 shows that the 
intensity of the endothelin-1 staining (endothelin-l-like immu- 
noreactivity) on the vascular endothelial cells of the pulmonary 
artery was more intense in the CHF rats than in the sham- 
operated rats. Results similar to those shown in Figure 3 were 
observed in six CHF rats and six sham-operated rats. However. 
the intensity of the endothelin-1 staining on the alveolar 
macrophages did not differ between the two rat groups (data 
not shown). 
The absorption test showed that the endothelin-l-like 
immunoreactivity was greatly reduced when the primary anti- 
body was absorbed with synthetic endothelin-1 (20 pmol/liter) 
(data not shown). indicating that the immunoreactivity was 
specific for endothelin-I. 
Elects of continaous IQ-123 infusion oo hemodyoamic 
variables and tissue weights. Continuous infusion of BQ-123 
(15 mg/rat per day) for 2 weeks caused sigltificant reductions in 
right ventricular systolic pressure (by 489. Fig. 4. left). right 
ventricular end-diastolic pressure (by 49%. Table 2) and 
central venous pressure (by 75%. Fig. 4. right) in the CHF rats. 
Fv 1. Typical examples of Northern blot analysis are shown for the 
level of preproendothelin-I (prepro ET-l) messenger ribonucleic acid 
(mRNA) in the lung of the shamqerated rats (Sham) and the rats 
with congestive heart failure (CHF) 7 weeks after operation. To 
normalize the preproendothelin-1 signals for the loaded amounts and 
transfer ellicieocies. beta (/3)-actin mRNA was considered and is 
indicated by a~. The expression of prcproendothelin-1 mRNA in 
the lung of the CHF rats was greatly increased. kb = kilobaw. 
Lung 
--n .w n 
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Figure 2. Typical examples of Northern blot analysis are shown for the 
level of prcproendothelin-1 (prepro ET-l) messenger ribonucleic acid 
(mRNA) in the kidney of the sham-operated rats (Sham) and the rats 
with congestive heart failure (CHF) ? weeks after operation. To 
normalize the preproendothelin-I signals for the loaded amollnts and 
transfer efficiencies. ethidium bromide staining of MS ribosomal 
ribonucleic acid (rRNA) was considered and is indicated by azzx. 
The expression of preproendothelin-1 mRNA in the kidney of CHF 
rats did not differ from that of sham-operated rats. kb = kilobase. 
Thus, continuous infusion of BQ-123 for 2 weeks greatly 
ameliorated pulmonary hypertension in the CHF rats. It did 
not affect mean blood pressure? left ventricular +dP/dt,, or 
left ventricular end-diastolic pressure in this group (Table 2). 
However, because we did not measure cardiac output or blood 
flow in the aorta, we cannot know how BQ-123 treatme,l: 
affected the afterlcId of the I& ventricle. 
Figure 3. Typic4 examples of endothelin-1 staining (endothelin-l-like 
immunoreactivity) in the rat lung demonstrated by the immunohisto- 
chemical method in a sham-operated rat (A) and a rat with chronic 
heart failure (CHF) (B) 2 weeks after operation. The endothelin-1 
staining (endothelin-l-like immunoreactivity) was observed as brown 
(arrows). The vascular endothelium was stained brown, indicating that 
endothelin-1 is distributed in the vascular endothelium of both rats. 
The intensity of the endothelin-I staining (endothelin-l-like immun+ 
reactivity) on the vascular endothelial cells of the pulmonary arteryzas 
stronger in the CHF rats than in the sham-operated rats. Reab!ts 
similar to those shown here were observed in six CHF rats and six 
sham-operated rats. 
’ 
,’ 
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The ratio of the weight of the,rigtt ventricle to body weight 
was signifi!antly higher in the CHE’ rats treated with saline 
solution than in the sham-operated rats treated with saline 
solution (1.26 -C 0.06 vs. 0.60 t- 0.02 mg/g, n = 6, p < 0.01). 
Long-term BQ-123 Jreatment significantly (p < 0.05) amelio- 
rated right ventricular hypertrophy. The ratio of the weight of 
the left ventricle to body weight did not differ among three 
groups; that is. the ratios in the sham-operated rats treated 
with saline solution, the CHF rats treated with saline solution 
and the CIiF rats treated with BQ-123 were 2.20 c 0.04, 
2.33 ? 0.06 and 2.36 2 0.09 (each n = 6), respectively. 
The mean myocardial infarct size in the CHF rats treated 
with saline solution (49 + 4%) was not different from that in 
the CHF rats treated with BQ-123 (50 + 5%). 
Discussion 
Effects of long-term treatment with an entiothelin receptor 
antagonist on pulmonary hypertension caused by CHF. At 2 
weeks after coronary artery ligation, congestive heart failure 
accompanied by pulmonary hypertension developed in the 
rats. The expression of preproendothelin-1 mRNA was mark- 
edly increased in the lung of the CHF rats and endothelin-1 
staining in the vascular endothelial cells of the pulmonary 
artery was more intense in the CHF rats than in the sham- 
operated rats. Furthermore, the present study demonstrated 
for the first time that long-term treatment with BQ-123, an 
endothelin-A receptor (ETA receptor) antagonist (18), greatly 
ameliorated pulmonary hypertension in the CHF rats, suggest- 
ing that an endothelin receptor antagonist may be a potential 
therapeutic agent for pulmonary hypertension caused by CHF. 
The latter finding is very important because pulmonary hyper- 
tension caused by CHF is resistant to many drugs and is often 
a progressive condition that ultimately leads to right heart 
failure and death (2). The present findings suggest that endog- 
enous endothelin-1 greatly contributes to the progression of 
pulmonary hypertension caused by CHF in rats. It has been 
reported that endothelin-l-induced vasoconstriction of the 
pulmonary artery is mainly mediated by endothelin ETA 
receptors in rats (6,25,26) and humans (27). 
JACC Vol. 2X. No. b 
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Fi 4. Bar gmplt shows the elfrcts of the 
coqlinuous infusion of BQ-13, an endothelin-A 
kceptor antagonist on the progression of pul- 
monary hypertension (left panel) and systemic 
congestion (right panel) in the rats with con- 
gestive heart failure (CHF). Sham = sham- 
operated rats. l p = 405; **p = <O.Ol. 
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Production of endothelin-1 in the pulmonaq vascular 
endotbelial celk in the CHF rats. Cody et al. (12) reported 
that plasma endothelin-1 concentration correlates with the 
extent of pulmonary hypertension in patients with CHF, 
suggesting that elevated circulating endothelin-1 is related to 
the change in lung conditions in these patients. However, 
controversy persists regarding the producfon of endothe!io-! 
in the lung in CHF. Tsutamoto et al. (28) showed that the 
plasma endothelin-1 level was increased significantly in plasma 
from the main pulmonary artery to that in the pulmonary 
capillary wedge region in patients with CHF, whereas Eaton et 
al. (29) reported the absence of pulmonary endothelin gradient 
in patients with normal or elevated circulating endothelin. 
Because the lung is an important organ for eliminating 
endothelin-1 from the circulation (17), the measurement of 
plasma endothelin-1 levels has limited ability to assess produc- 
tion of endothelin-1 in the lung. In the present study, our 
findings are novel in that we have directly demonstrated that 
the production of endothelin-1 in the lung is increased in CHF. 
because the expression of preproendothelin-1 mRNA in the 
lung was greatly increased in the CHF rats. As the expression 
of preproendothelin-I mRNA in the kidney did not differ 
between the CHF rats and the sham-operated rats, the in- 
crease in endothelin-1 production is a relatively specific phe- 
nomenon in the lung of the CHF rats. The present immuno- 
histochemical study also revealed that endothelin-1 staining in 
Table 2. Hemodynamic Variables of Sham-Operated Rats and CIIF 
Rats Given BQ-123 or Saline Infusion for 2 Weeks 
Group 
mBP LV + dP/d&, LVEDP RVEDP 
(mm W (mm W) (mm Hg) (mm W 
Sham t saline 11624 9,040 2 176 3.4 r- 0.7 1.9 c 0.3 
(n = 6) 
CHF t saline 86 + 3’ 5,520 + 278’ 21.7 2 1.4’ 11.3 ? 0.8’ 
(n = 6) 
CHF + EW-123 82 it 3’ 5.467 + 313’ 21.2 2 1.1’ 6.7 r 0.6’t 
(n = .6) 
‘p < 0.01 vetsus the corresponding value for Sham + salti rats. tp ,< U.01 
versus the cqrespondii value for CHF + saline rats. Valu& presented are 
mean value % SEM. CHF + BQ-123 = CHF rats given continuous RQ-12.3 
infusion for 2 weeks, CHF + saline = CHF rats given continuous saline infusion 
fa 2 wels; Sham + saline = sbm-operakd rats given contimmus saline 
inhtsion for 2 weeks Other alkviations as in Table 1. 
(mmHg) es N.S. 
2 
h” 
$3 
E 
P* 
El 
5” 
ctF+hla 
Sham+Salina CW+Bo-123 
the vascular endothelial cells of the pulmonary artery was more 
intense in the CHF rats than in the sham-operated rats. 
Therefore. it is suggested the increased peptide level of 
endothelin-1 in the pulmonary vascular endothelial cells in the 
CHF rats is attributed td; the increase in the endothelin-1 gene 
transcription. 
The reason for the enllanced expression 9f preproendothelin- 
1 mRNA in the lung of ChF rats remains to be elucidated. It has 
been repotted that the expression of preptuendorhelin-I mRNA 
was increased by hemodynamic shear stress in alltured vascular 
endothelial cells (30) and that pure pressure without shear stress 
or stretch enhanced thf: release of endothelin-1 in cultured 
human endothelial cells (31). These results suggest that pmduc- 
tion of endothelin-I in vascular endotbelial ,?eUs may be increased 
by mechanical factors Therefore, it can be assumed that hem& 
dynamic overload to the pulmonary vzsc.llar endothelium by 
pulmonary hypertension causes the increase in the expression of 
preproendothelin-1 mRNA in the pulmonary vascular endothe- 
lium in CHF rats. This argument is in agreement with our finding 
(32) that elevated levels of circulating plasma endothelin-1 in 
young patients with pulmonary hypertension caused by congenital 
heart disease were decreased in accordance with amelioration of 
pulmonary hypertension by sucu5sM sqical repair. 
Expressiou of embtbelia-1 in pbnnwy hypertensiw dee 
tu difemnt eWugies. Plasma endothelin-1 concentration was 
reported to be elevated in animal models qf pulmonary 
hypertension caused by lung diseases (i.e.. r;ts with pulmonary 
hypertension induced by hypoxia [33] or monocrotaline [S]). In 
rats with monocrotaline-induced pulmonary hypertension a rat 
model of pulmonary hypertension caused by inflammatory 1Lng 
disease, we (34) reported that the intensity of endothebl 
staininginthepulmonaryarterywassameasthatincontrdrats 
whereas the intensity of endothelin-1 staining in the alveolar 
mactupbages was markedly inaead. In patients with pulmonaiy 
hypertension caused by noninflammatory lung disease or m 
genie m arteriopatby, Giaid et al. (35) reported that tbe 
expnzssion of endotbelin-l is increased in the pulmonary vascular 
,endothelial ceils. 
-!kkctive ekets of IQ-123 00 the pmlnosug circuit to 
lomrarteIidprrsJrrrwltbont~ectiagthepassiveeom~ 
neotofpabonagbypehhniaCHF. Inthisstudy.BQ- 
I23 affected neither left ventricular +dP/dt,, nor left ventric- 
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ular end-diastolic pressure. indicating that it did not affect the 
impaired functron of the left ventriclein the CHF rats. Thus. 
the administration of BQ-123 for 28 weeks did not affect the 
condition .of left heart failure in rats with CHF. It has been 
considered that the pulmonary hypertension seen ‘in isolated 
left heart failure is due. to predominantly passive phenomena 
caused by elevated left-sided pressures (1). Neverthclcss. the 
present study showed that long-term BQ-123 treatment greatly 
reduced pulmonary artery prcssurc but not systemic artcrial 
pressure in the CHF rats. Thus. BQ-123 selectively reduced 
pulmonary artery pressure in the CHF rats. One possible expla- 
nation for this finding is that there is a major vasoactive compo 
nent to pulmonary hypertension seen in left heart failure and 
endothclin-1 may be a candidate for the component. 
It has been reported that endothelin-l-induced vasocon- 
striction in various rat arteries that participate in the regulation 
of the systemic circulation is mainly mediated by ET,\ recep- 
tors (25) and that BQ-123 greatly antagonizes the prcssor 
effect of exogenously applied endothelin-I in rats (16.18,36). 
Thcrcforc, WC consider that the difference between the effects 
of BQ-123 on pulmonary artery pressure and on systemic 
pressure may be attributed to the difference in the production 
of endothelin-I in the vascular endothelium between the 
pulmonary and systemic circulations in the CHF rats. This 
consideration is partly supported by the finding that the 
expression of preproendothelin-1 mRNA in the CHF rats is 
increased in the lung but not in the kidney. 
Our previous study (16) showed that short-term adminis- 
tration of the ETA receptor antagonist BQ-123 did not alter 
mean blood pressure in the CHF rats. However. Teerlink et al. 
(37) reported that short-term administration of the ETA/ 
endothelin-B (ETB) combined receptor antagonist bosentan 
lowers hlood pressure in rats with CHF due to myocardial 
infarction. One possible explanation for the discrepancy in 
short-term effects on systemic blood pressure between BQ-123 
and bosentan is that the blockade of both ETA and ETB 
receptors by hosentan may contribute to its blood pressure- 
lowering effect in CHF rats, because both ET,+mediated and 
ET&mediated mechanisms for vascular contraction exist in 
various vessels (625). In the present study, long-term BQ-123 
treatment did not affect mean arterial pressure in the CHF 
rats. However, it is not known whether long-term treatment 
with ETA/B combined receptor antagonists affects systemic 
blood pressure of the CHF rats. In patients with severe chronic 
heart failure (New York Heart Association class III), Kiowski 
et al. (38) reported that short-term (2-h) infusion of the ETA/u 
combined receptor antagonist bosentan significantly reduced 
mean systemic arterial pressure by 7.7% and pulmonary artery 
pressure by 13.7%. However, there is no report whether 
long-term treatment (at least 2 to 3 weeks) with endothelin 
antagonists alters systemic arterial pressure or pulmonary 
artery pressure in patients with chronic heart failure. 
Effects of endothelin receptor antagonists on niyocardial 
infarct size. This heart failure model-that is, rats Gth myo- 
cardial infarction-is well established, and some investigators 
have reported the effects of endothelin antagonists on this 
model. Controversial tindings were reported in several studies 
concerning the effects of endothelin antagonists on myocardial 
infarct size. Wdtan’abe et al. reported that a monoclonal 
antibody against endothelin-1 (39) or the ET/de receptor 
antagonist TAR-044 (40) reduced myocardial infarct size in 
this model. and Lee et al. (41) also reported that the ,ETA 
rcccptor antagonist FR-13Y3 17 reduced myocardial infarct siie 
in this model. However. in a rabbit model of acute myocardial 
ischcmia and reperfusion. McMurdo et al. (42) ohs:rved that 
FR-139317 had no cffcct on infarct size. In the present study. 
the ET,\ receptor antagonist BQ-123 had no effect on the 
infarct size. in accordance with the study’s finding that long- 
term (2 weeks) BQ-123 treatment did not affect left ventricular 
+dP/dt,,, or left ventricular end-diastolic pressure in the CHF 
rats. The reason for these differences among studies is unclear. 
Study limitations. In the present study, treatment with 
BQ-I23 was started on the day after infarction and continued 
for 2 weeks. This time period was selected for assessment of 
the long-term effects of BQ-123 on the pulmonary hyperten- 
sion caused by CHF, because we (16) have previously found in 
this modal that at this stage CHF-induced pulmonary hyper- 
tension is marked but myocardial hypertrophy of the surviving 
myocardium in the left ventricle is less markrd. .9t later stages 
(several months after infarction). we observed (unpublished 
data) that significant myocardial hypertrophy occurs in this 
animal. In the present study, BQ-123 treatment over a 2-week 
period did not affect the impaired function of the left ventricle 
in the CHF rats despite significant reductions in right ventric- 
ular systolic pressure and central venous pressure. Thus, BQ-123 
greatly ameliorated right heart failure in the CHF rats without 
ameiiorating the condition of left heart failure in these rats at this 
stage. However, because an endnthelin receptor antagonist has 
been reported to prevent cardiac hypertrophy in vitro (6,43) and 
in vivo (6.844). it remains to be assessed whether longer treat- 
mcnt periods (e.g.. several months) would ameliorate left ventric- 
ular remodeling (hypertrophy of cardiac myoqtes in the surviving 
myccardium, cavity enlargement of the left ventricle, among 
others) or the left heart failure in the CHF rats. 
In the present study, we did not investtgate whether Iong- 
term BQ-123 treatment affects the preproendothelin-1 mRNA 
expression or endothelin-l-like immunoreactivity in the lung 
of CHF rats. Therefore, it is still unclear whether long-term 
BQ-123 treatment affects the regulation of endothelin-1 pro- 
duction in the lung of CHF rats. 
Our previous report (8) indicated that marked thickening of 
the vascular walls of the pulmonary artery occurred in the rats 
with pulmonary hypertension caused by inflammatory lung 
disease due to monocrotaline and that long-term treatment 
with BQ-123 greatly inhibited this thickening. However, the 
present study showed slight thickening of the vascular walls of 
the pulmonary artery in the CHF rats (Fig. 3); therefore, it is 
difficult to assess whether long-term BQ-123 treatment inhibits 
the thickening of the vascular walls of the pulmonary artery in 
CHF rats. The CHF rats used in the present study were studied 
2 weeks postoperatively; however, we have found (unpublished 
observation) that the marked thickening of the vasculrrr walls 
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of the pulmonary artery ,occurs in the CHF rats 3 months 
postoperatively. Therefore. additional study using the CHF rats 3 
months postoperatively is required to resolve this question. 
In the: present study. right ventricular systolic pressure of 
the sham-operated rats appeared to be relatively higher than 
that iri humans. .Because we measured the right ventricular 
pressure with a fluid-filled system at high heart rates (--330 
beatdmin), we consider that the time constant was not suffi- 
cient to allow an adequate response, and this may be a redson 
for the relatively high pressure. 
Conclusions. The expression of preproendothelin-I mRNA 
was greatly increased in the lung of the CHF rats and the 
endothelin-1 staining in the vascular endothelial cells of the 
pulmonary artery was more intense in the CHF rats than in the 
sham-operated rats. Furthermore, continuous infusion of BQ- 
123 for 2 wczks greatly ameliorated pulmonary hypertension in 
the CHF rats. Therefore, the present study suggests that 
endogenous endothelin-1 contributes to the progression of 
pulmonary hypertension caused by CHF in rats and that an 
endothelin receptor antagonist may be a new therapeutic agent 
for pulmonary hypertension caused by CHF. 
WL’ acknowledge Masaru Nishihihe. MD for useful dirusrions. 
References 
1. Smith TW. Hea;; failure. In: Wyngaarden JB. Smith LH. Bcnne1t JC. 
editors. Cecil Tcxthrok of Medicine. Philadelphia: Saunders, 1992:187-207. 
2. Fishman AP. Pulmonatv hypertension. In: Wyngaardcn JB. Smith LH. 
Bennett JC. editors. C&l Textbook of Medicine. Philadclohia: Saunders. 
1992:269-80. 
3. Yanagisawa M. Kurihara H. Kimurd S. CI al. A novel poten: vasoconstrictor 
pcptide produced by vascular cndothclial cells. Nature 1!/8833?4l l-5. 
4. Miyduchi T. Tom&e Y. Shiba R. EI al. Involr~mcnt of endotbelin in the 
regulation of IrJman vascular tonus. Potent vasoconstrictor zkcr and 
existence in endothelial cells. Cilrulation 1990;81:1874-86. 
5. Masaki T. Kimura S. Yanagisawa M. Go10 K. Moleculdr and cellular 
mechanism of endothelin regulation: implication for vascuh function. 
Circulatiun 1991;84:1457-68. 
6. Ruhanyi GM. Polokof MA. Endothelins: molecular biology. hiochcmistty. 
pharrnamlo& physiology. and pathology. Pharmacol Rev 199J:4C:PS-4l5. 
7. Ryan US. Glassberg MK, Nolop KB. Endothelin-I from pulmonary artery 
and microvmls acts on vascular and airway smooth muscle. J Cardiovau 
Pharmarql 1989:13%57-62. 
8. Miyauchi T. Yorikane R, Sakai S. EI al. Contribution of endog-:nnus 
endothelin-I IO the progression of cardiopulmonary alterations in rats with 
monocrotahnc-induced pulmonq hypertenstor. Ctrc Res 1993;73:887-97. 
9. Lippton HL Hauth TA. Summer WR, Hyman AL. Endothelin produces 
pulmonary vasoeonstriclion and systemic vasodilation. J Appl Physiol lYH9: 
fr6:1IkI8-12. 
IO. B&ik A Grooms A Millar JA Mitchell A Grirtpukel S. Growlh factor activity 
of endothelin on vascular smooth muscle. Am J Ilrysiol 1:%258CU)8-15. 
11. Takuwa N. Taktnva Y. Yanagisawa M. Yamashita K. Masaki T. A novel 
vasoactive pcptide endothelin stimulatLs sitngencsis through inositol lipid 
turnover in Swiss 3’13 fihroblasts J Biol Chem I989:264~7856-61. 
’ 12. Cody RJ, Haas GJ, Binkky PF. Capers 0. Kelly R. PIasma endothelin 
correlates with the extent of pulmonary hypertension in patients with chronic 
mngestivc heart failure. Circulation 1992;851#-Y. 
13. Stewart DJ. Cemaeck P, Costello KB. RouIeau JL Ekvated endothelin-I in 
heart failure and loss of normal response’ to postural change.’ Circulation 
1992;85510-7. 
14. Cacoub P, Domet R. Nataf P. et al. ‘Plasma endolhelin and pulmonary 
24. Knha~arhi M. Nishikibc 51, Maruyama H. UI al. Locraliwtinn and alteration 
of immunorcactive endothelin-I m canine basilar arteries following suh- 
arachnoid hcmorrhagc. Acta Histuchem Cytochcm 1992:2X:129-36. 
2.5. Davenport AP. Maguirc JJ. Is endotholin-induced vasoconslriction mediarcd 
only hy ET-\ receptors in humans’! Trends Pharmacol Sci lW$lS:9-I I. 
26. Watanabe TX. Itahara Y. Ndkajima K. Kumagaye S. Kimura T. Sakakihara 
S. The biological acttvity of cndothelin-1 analugucs in three diffcrrnt assay 
systems. J Cardiovasc Pharmacol 1991:17:s5-9. 
27. Fukurctia T. Kobavwhi M. Ozaki S. et al. Endothclin rcccptor subtypes in 
human versus rabbit pulmonary arteries. J Appl Ph!siol 1994:7h:I97h-82. 
IS. Tsutamotn T. Wada A. Maeda Y. Adachi T, Kinoshitra M. Relation between 
cndothelin-I spillnver in the lungs and pulmonary vascular reristancc in 
paticntr with chrnnic hcdrt failure: J Am &II Cardiol 199+23:lJ21-33. 
Eaton GM. Bush CA VanFosscn DB. Kclky RE. Cody RJ. Abscrt~e of 
pulmonary rndothelin gradient in patients with normal or clrvated circulat- 
ing endothelin. Am J Cardiol lW1;72:1ltIS-6. 
Morita T. Kurihara H. Marmura K. Yoshisumi M. Nagai R Yazaki Y. Role 
uf Ca’ and protein kind= C in shear stress-induced actin depolymertzation 
and endothclin-I gent expression. Circ Res 1994:75.630-b. 
Hishikawa K. Nakaki T. Marumo T. Suzuki H. Kato R. Saruta T. Pressure 
enhances endothelin-I release from cultured human endothrlial cells. Hy- 
pertension 1995:25&I9-S2 
29. 
30. 
31. 
32. 
33. 
34. 
35. 
Ishikawa S. Miyauchi T. Sakai S. et al. Elevated Ievcls of plasma endahclin-I 
in young patients with pulmonaF hypertension caused by congenital heart 
dirasc arc decrcascJ after successful surgical repair. J J%rac Cardiovar 
suq I995:I )1):271-3. 
Li H. Chcn SJ. Chrn YC. et al. hhdncrr: cndothclin-I and mdoihclin 
receptor gene rxpr&;n in chronic Fqroxie J Appl Physiol 199&77:1451-Y. 
Sakai S. hlivauchi T. Yamaguchi I. SugiSntta Y. Golo K. Kohavashi M. Study 
of endotheiin-1-like: immunoreactivity in the lung of rats with pulmonaty 
h!Frtension caused by mnnocrotaline [abstract]. Jpn Circ J 1995595~7. 
Giaid A Yanagisawa M. Iangkben D. et al. Expression of endothelin-I in 
the lungs of patirnts with pulmonaty hypcrtmsion. Ii Engl J Yed 1993328, 
1732-9. 
36. 
37. 
.w. 
Nishikibe hi. Tsuchida S. Okada M. et al. Antihypertenrire effectsof a newly 
.svnthesizcd endolhelin antaaonist. BQ-13. in a acnetic hvpertensivc model. 
Life .Sci 199352:717-2-I. - 
. . 
Teerlink JR, Lo& BM. Hess P. Maire JP. CIozel M. Clozel JP. Role of 
endothelin’ in the maintenance of Mood prcxsure tn conscious rats with 
chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 
47-0203 (Boseman). Circulation 1994:98:25ltJ-8. : - 
Kim&i W. Sutseh G. Hurtziker P. et al. Evidence for endothelin-I-mldiated 
vasocomtriction in sevcrc chronic heart failure. Lancct 1995%732-6. 
prcs+ures in patients wt!h ctmgestive heart failure. Am Heart J 1993:12b: 
14%8. 
15. Xlargulis\ KB. Hildcbran:l FL Jr. Lcrmsn X. PL’rrcIIa MA. Burnstt JC Jr. 
Incrca\cd cndothclin-1 in espcrimental heart failure. Circulation IWU:X!: 
“‘6-30. --- 
16. Sakai S. Mivauchi T. Sakurai T. ct al Endugcnou\ cndothclin-I particip;;tss. 
in the m~tinlcn;mcz of car&c functionin rats with congrstive heart failure. 
Xlarkcd incruar in cndothelin-I production in the failing heart. (‘irculatitm 
IYYfl:93:12I-I-22. 
17. Shiha R. Yanagirawa bl. Miy;:uchi T. L’I al. Eiimination ol intravcnuusl~ 
injcrtcd cndnthclin~l from circ&uiun of the rat. ! Cardiovar Pharmacol 
1989:13:SYri-Iill. 
18. lhara M. Noguchi K. bcki T. SI al. Biological profiles of highly pofcnt novel 
cndothclin antagonisti sckctivc for the ET\ receptor Life SKI IW2:f;tl:247-55. 
19. Pfcffcr MA. PI&r JY. Fishbein MC. ct al. Mylwsrdial infarct sife and 
ventricular function in ruts. Circ Rcs 197Y:U:Stl3-12. 
20. Pfcffer MA. Pfelkr JM. Stuinbcrg C. Finn P. Survival after an cxperimcntal 
myocardial infarction: beneficial effecrs of long-term therapy uith captopril. 
Circulation 198S:72:406-12. 
21. Tcerlink JR. Goldhahrr SZ. Pfckr MA. An overview of contemporary 
ctiologics of congestive heart failure. .Am Heart J I99l:lZl:l852-3. 
22. Mivauchi T. Yanagisawa M. Tomizawa T. CI al. Increased plasma concen- 
trations of endothelin-1 and hig endothelin-1 in acute myocardial infarction. 
Lanrcl I9XU:16453-4. 
23. Sakurai T. Yanagisawa M. Inouc A. ct al. cDNA cloning. scqucncc analysis 
and tissue distribution of rat preproendothclin-I mRNA. Biochcm Biophys 
Rra Commun 199l:l75:U-7. 
1586 SAW1 ET AL. JACC Vol. 2X. No. h 
ENDOTliELIN-1 AAiE i’Gl.MONARY HYPERTENSION DUF: TCJ CHF Nwzmher IS. IQ!J(KISKILX 
79. Watanahc T. Suzuki N. Shimamoio N, Fujino M.. imada A. Cootrihution 01 
rndo,ocnou\ cndothclin to the exfcnJion ;?f mycardial infarct size in rats. 
Circ Rcs lY91:6Y:3il~-7. 
411, Watanabe T, Awanc Y. Ikcdn S. CI ;+I. Pharmacoh@ of a non-sclrctivc 
ETxETs rcwptor antagonist. TAK-044 and the inhihirion ~,f myxardi;rl 
infarct six in rstr. Br J Pharmacol 19Y5;114:91Y-54. 
11. I& JY. Warner RB. Adler AL, Opgcnorth TJ. Endorhclin ET!\ rcceptor 
antagonir~ reduces mycurdial infarction induced h! cornnary artcry occlu- 
rion nnd repcrfusion m the rat. Pharmacoltrbq 1994:JY:.~lY-11. 
43. McMurdo L: Th~emcrmsrrn c’. Vane JR. Thr cftects of the wdothelin ETA 
receptor anragonisr. FR 139317. on infarct six m r rabbit mtdrl of acute 
myxardial irhemia and rcpsrfuGnn. Br J Pharmacol lY93:112:75-Nl. 
43. Shuhciia HE. McDonough PM, Harris A;J. ef al. Endothelin induction of 
inositol phosphnlipid hydrolysis. wcomere arsemhly. and cardiac gene 
expression in wnfrirular mycges. J Biol Chcm 199Wh5:?0555-62. 
J1. Ifo H, Hiror M. Hirata Y. CI al. Endofhrlin ETA rcccptur antagonist blocks 
cardiac hycrtrophy prowkcd hy hcmodyamic owlcad. Circularitm 1994: 
89:?lYX-‘Ill - . 
